Lumenis OptiLight is the first and only intense pulsed light (IPL) device to be approved by the United States Food and Drug Administration (FDA) for the management of dry eye disease due to meibomian gland dysfunction.1
Backed by 70+ clinical studies, and 60 years of innovation, OptiLight was developed specifically for eye care professionals, by eye care professionals.2
OptiLight exclusively integrates Lumenis, the inventor of IPL clinically proven, patented technologies – the OPT handpiece, which treats the delicate facial contours of patients, and the ergonomic IPL handpiece, which treats wider areas safely and comfortably with patented SapphireCool technology to effectively break down the vicious cycle of dry eye inflammation.
Contact: OptiLight (AUS) 1800 586 364 or (NZ) 0800 239 015.
References
- FDA study sponsored by Lumenis: internal reference LUM-VBU-M22-IPL-17-01.
- OptiLight clinical studies booklet. Available from Lumenis.
